Introduction
Spusoft Syrup 175 mg/5 ml is a drug that causes a breakdown of mucus, also known as a mucolytic agent. It is a thiol derivative produced for the clinical management of chronic obstructive bronchitis, in addition to infective exacerbations of chronic bronchitis. This drug contains sulfhydryl groups which are released after erdosteine undergoes hepatic first pass metabolism. Three active metabolites result and possess mucolytic activity in addition to free radical scavenging activity. Spusoft Syrup 175 mg/5 ml acts to control mucus production and control its viscosity while increasing mucociliary transport. It also combats the effects of free radicals resulting from cigarette smoke. Spusoft Syrup 175 mg/5 ml has been shown to be safe and well tolerated in clinical trials. Spusoft Syrup 175 mg/5 ml 300mg twice daily reduced cough (both frequency and severity) and sputum viscosity more quickly and more effectively than placebo and reduced the adhesivity of sputum more effectively than ambroxol 30mg twice daily. Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier and more pronounced amelioration of clinical symptoms compared with placebo. Spusoft Syrup 175 mg/5 ml is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild.
Uses
Spusoft Syrup 175 mg/5 ml is a mucolytic agent used to treat conditions characterized by pathological mucus such as respiratory tract infections and chronic obstructive pulmonary disease (COPD).
Fro the treatment of chronic bronchitis in adults.
Associated Conditions
Mechanism of Action
Spusoft Syrup 175 mg/5 ml, is an orally administered mucolytic agent. It is classified as a thiol derivative and produced for the management of symptoms caused by chronic obstructive bronchitis. Spusoft Syrup 175 mg/5 ml contains sulfhydryl groups which are released after hepatic first-pass metabolism in the liver. Its active metabolites (3 in number) exert both mucolytic activity and scavenging activity against free radicals. Spusoft Syrup 175 mg/5 ml acts to regulate the production of mucus in the airway and regulates its viscosity while enhancing mucociliary transport. This leads to an increase in expectoration. Spusoft Syrup 175 mg/5 ml shows inhibition against the effects of free radicals from cigarette smoke. Clinical studies in patients with chronic obstructive lung disease (COPD) have shown that this drug is generally safe and well tolerated. Spusoft Syrup 175 mg/5 ml 300mg twice daily reduced cough (both frequency and severity) and sputum viscosity more quickly and more effectively than placebo and reduced the adhesivity of sputum more effectively than ambroxol 30mg twice daily. Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier and more pronounced amelioration of clinical symptoms compared with placebo. Spusoft Syrup 175 mg/5 ml is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild.
